Back to Search
Start Over
Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus.
- Source :
-
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2021 Aug 30; Vol. 11 (9). Date of Electronic Publication: 2021 Aug 30. - Publication Year :
- 2021
-
Abstract
- More than half of the patients with heart failure have preserved ejection fraction (HFpEF), however evidence shows a mortality rate comparable to those with reduced ejection fraction. The aim of this study was to evaluate whether FGF21, galectin-3 and copeptin can be used as biomarkers to identify HFpEF in patients with confirmed type 2 diabetes mellitus (DM). Sixty-nine diabetic patients were enrolled and divided into two groups: patients with HFpEF ( n = 40) and those without HFpEF ( n = 29). The ability of the studied biomarkers to discriminate HFpEF cases from non-HFpEF subjects were evaluated by the area under the Receiver Operating Characteristics (ROC) curve and the 95% confidence interval (CI). Compared to patients without heart failure, those with HFpEF had significantly higher levels of FGF21 (mean 146.79 pg/mL vs. 298.98 pg/mL). The AUC value of FGF21 was 0.88, 95% CI: [0.80, 0.96], Se = 85% [70.2, 94.3], Sp = 79.3% [60.3, 92.0], at an optimal cut-off value of 217.40 pg/mL. There was no statistical significance associated with galectin-3 and copeptin between patient cohorts. In conclusion, galectin-3 and copeptin levels were not effective for detecting HFpEF, while FGF21 is a promising biomarker for diagnosing HFpEF in DM patients.
Details
- Language :
- English
- ISSN :
- 2075-4418
- Volume :
- 11
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Diagnostics (Basel, Switzerland)
- Publication Type :
- Academic Journal
- Accession number :
- 34573919
- Full Text :
- https://doi.org/10.3390/diagnostics11091577